ライフサイエンスコーパス: cidofovir

1 mmunosuppression and treatment with low-dose cidofovir.

2 ted B-cell(-/-) mice with the antiviral drug cidofovir.

3 There was little net directional movement of cidofovir.

4 was resistant to ganciclovir, foscarnet, and cidofovir.

5 sporting the nucleotide analogs adefovir and cidofovir.

6 lues > or =30 microM and cross-resistance to cidofovir.

7 s ganciclovir followed by foscarnet and then cidofovir.

8 ted with in vitro cross-resistance of CMV to cidofovir.

9 for CMV isolates that are cross-resistant to cidofovir.

10 o ganciclovir, and 4 were cross-resistant to cidofovir.

11 events considered to be possibly related to cidofovir.

12 d for 50% inhibitory concentration (IC50) of cidofovir.

13 asing levels (from 5 to 75 micrograms/ml) of cidofovir.

14 ed that demonstrated increased resistance to cidofovir.

15 enhancement over the FDA-approved antiviral cidofovir.

16 ex virus (HSV) replication than acyclovir or cidofovir.

17 mmunosuppression reduction and half received cidofovir.

18 selectivity indexes that approximate that of cidofovir.

19 A synthesis apparatus that are distinct from cidofovir.

20 ganciclovir, valganciclovir, foscarnet, and cidofovir.

21 ted contribution to the urinary excretion of cidofovir.

22 ted HHV-8 replication to a similar degree as cidofovir.

23 ting toxicity, particularly for adefovir and cidofovir.

24 seven patients were treated with intravenous cidofovir (0.20-0.50 mg/kg) every two to four weeks over

25 ients were treated with intravenous low-dose cidofovir (0.25-1 mg/kg per dose, every 2-3 weeks, witho

26 Cidofovir (0.3% or 1%) or placebo gel was applied once d

27 0.5% ketorolac tromethamine; group III, 0.5% cidofovir + 0.1% diclofenac sodium; and group IV, contro

28 cidofovir + artificial tears; group II, 0.5% cidofovir + 0.5% ketorolac tromethamine; group III, 0.5%

29 Cidofovir 1 mg/kg intravenously three times per week was

30 ate hexahydrate) (IC50 = 80-100 microM), and cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]c

31 Cidofovir [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]c

32 ters of 99 000-2 500 000 copies/mL) received cidofovir; 1 died from complications relating to adenovi

33 6 eyes pretreated with liposome-encapsulated cidofovir 10-60 days before HSV-1 inoculation were prote

34 Cidofovir (100 micrograms) in liposomes (0.1 mL) was inj

35 Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 wee

36 Moreover, treatment with cidofovir, a potent antiviral agent, robustly inhibits t

37 ed saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate an

38 oted for HCMV during the various regimens of cidofovir administrated in this clinical trial.

39 red treatment group were eligible to receive cidofovir after progression of CMV retinitis was documen

40 in vitro studies indicating the efficacy of cidofovir against different adenovirus serotypes and sup

41 localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet.

42 eported in 31 (37%) of 84 patients allocated cidofovir and 39 (46%) of 84 patients assigned imiquimod

43 e study; 89 patients were randomly allocated cidofovir and 91 were assigned imiquimod.

44 The affinity of hOAT1 toward cidofovir and adefovir (K(m) = 46 and 30 microM, respect

45 nificantly contribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, th

46 the dose-limiting clinical adverse effect of cidofovir and adefovir, two potent antiviral therapeutic

47 In the retina, cidofovir and an unknown metabolite were detected in the

48 1 (46%; 90% CI 37.0-55.3) patients allocated cidofovir and by 42 (46%; 37.2-55.3) patients assigned i

49 prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol c

50 Cidofovir and control were administered to both eyes twi

51 However, coadministration of cidofovir and Dryvax also reduced vaccine-elicited immun

52 ine efficacy showed that coadministration of cidofovir and Dryvax compromised the Dryvax-induced immu

53 Thus, the single-dose coadministration of cidofovir and Dryvax effectively controlled vaccination

54 ldren, with BKVAN were treated with low-dose cidofovir and followed prospectively.

55 r resistance (<6-fold) but were sensitive to cidofovir and foscarnet, and 7 showed moderately reduced

56 o currently available antiherpesvirus drugs, cidofovir and foscarnet, had no effect on the transcript

57 S) conferred various levels of resistance to cidofovir and ganciclovir.

58 derately reduced susceptibility (<8-fold) to cidofovir and high-level resistance (8- to 23-fold) to g

59 Cidofovir and imiquimod were active, safe, and feasible

60 , and feasibility of two topical treatments--cidofovir and imiquimod--as an alternative to surgery in

61 the incremental health benefits and costs of cidofovir and immunosuppression reduction compared with

62 Cidofovir and Leflunomide are used empirically in the tr

63 The in vitro activity of Cidofovir and Leflunomide is modest, and the selectivity

64 mpared with those obtained with topical 0.5% cidofovir and saline.

65 ceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were

66 ration at phosphorus in cyclic (S)-HPMPC (1, cidofovir) and (S)-HPMPA (2) phenyl ester (5 and 6, resp

67 ermore, antiviral treatment with CMX001 (HDP-cidofovir) and ST-246 protects when administered as a re

68 conferred resistance to both ganciclovir and cidofovir, and a mutation at codon 802 of Pol conferred

69 the organ-specific toxicity of adefovir and cidofovir, and indicates that CHOh OAT cells may represe

70 Despite treatment with corticosteroids, cidofovir, and intravenous immune globulin, PML progress

71 Acyclovir, foscarnet, cidofovir, and PMEA reduced the number of cells expressi

72 Acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir) are eliminated predominantly i

73 ptake likely plays a role in the etiology of cidofovir- and adefovir-associated nephrotoxicity, we at

74 pical treatment groups: 3% ddC; 2% ddC; 0.5% cidofovir; and saline.

75 Cidofovir appeared safe and effective for the treatment

76 ravitreal injection of liposome-encapsulated cidofovir appears to have a remarkably potent and prolon

77 four masked treatment groups: group I, 0.5% cidofovir + artificial tears; group II, 0.5% cidofovir +

78 ation of topical corticosteroids and topical cidofovir as a desirable strategy for the treatment of s

79 ulating viral DNA replication and introduces cidofovir as a possible drug for controlling MCPyV infec

80 tially reported using ganciclovir and cyclic cidofovir as the prototype compounds.

81 n prior to, during, and after treatment with cidofovir, as well as species analysis of contemporaneou

82 travitreously injected with 20 micrograms of cidofovir at 5- to 6-week intervals.

83 Topical 1% and 0.5% cidofovir both appeared to be significantly more efficac

84 The lipid-conjugated prodrug of cidofovir, brincidofovir, has improved oral bioavailabil

85 A mutant exhibited an increased affinity for cidofovir but was not significantly different for PAH.

86 ptimal treatment strategies for BKVAN before cidofovir can be recommended strongly as routine therapy

87 vious studies showed that the CDV and cyclic cidofovir (cCDV) analogs 1-O-hexa-decyloxypropyl-CDV (HD

88 The acyclic nucleoside phosphonate cidofovir (CDV) and its closely related analogue (S)-9-(

89 We report our experience with cidofovir (CDV) for treatment of ADV infection in 57 HSC

90 Cidofovir (CDV) given by parenteral injection has been s

91 Group 1 was administered 1% cidofovir (CDV) twice a day for 3 days plus comfort tear

92 Cidofovir (CDV), a broad spectrum anti-DNA viral agent,

93 trial was conducted to test the activity of cidofovir (CDV), a drug with in vitro activity against K

94 We used cidofovir (CDV), a nucleotide-analogue KSHV DNA polymera

95 orally active ether lipid ester analogues of cidofovir (CDV)--hexadecyloxypropyl-CDV (HDP-CDV) and oc

96 determine the antiviral resistance of three cidofovir (CDV)-resistant variants of adenovirus type 5

97 Cidofovir [CDV; (S)-1-(3-hydroxy-2-phosphonomethoxyethyl

98 We also demonstrate that hexadecyloxypropyl-cidofovir (CMX001) rescues the hamsters from a lethal ch

99 d increased resistance to both foscarnet and cidofovir, compared with the wild-type CMV.

100 comprised of Dryvax and an antiviral agent, cidofovir, could reduce vaccinia viral loads after vacci

101 med Vgamma2Vdelta2 T cells in vaccinia virus/cidofovir-covaccinated macaques mounted major recall-lik

102 te significant lymphopenia (Brincidofovir vs cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte c

103 Topical treatment with 1%-cidofovir cream (twice daily for 7 days) was much more e

104 Cidofovir delayed but did not prevent the death of inl i

105 Rabbit study 1: 2.5%, 2.0%, 1.0% NCT, and cidofovir demonstrated significantly fewer positive cult

106 .1% NCT/1.0% NH4Cl, 0.1% NCT/0.1% NH4Cl, and cidofovir demonstrated significantly fewer positive cult

107 nt treatment of ketorolac or diclofenac with cidofovir did not diminish its antiviral inhibitory acti

108 f cellular metabolites showed that levels of cidofovir diphosphate (CDV-DP), the active antiviral com

109 further to the active antiviral metabolite, cidofovir diphosphate.

110 -treated eyes received the authors' standard cidofovir dose regimen: twice daily for 7 days.

111 The 0.5% cidofovir exhibited the most ocular toxicity compared wi

112 susceptibility among 29 paired pre- and post-cidofovir exposure isolates from 22 patients enrolled in

113 ddC was more potent than cidofovir for seven of nine serotypes.

114 The efficacy of cidofovir for treatment of cowpox virus infection in BAL

115 ir therapy showed complete susceptibility to cidofovir, ganciclovir, and foscarnet.

116 The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive he

117 th 20 micrograms of intravitreously injected cidofovir, given at 5- to 6-week intervals, is safe and

118 Five patients in the cidofovir group and seven in the imiquimod group either

119 AD5 variants in tissue culture resistant to cidofovir has important clinical implications with respe

120 virals discussed, including valacyclovir and cidofovir, have not yet been studied in children, but th

121 nging, and salvage therapies, foscarnet, and cidofovir, have significant toxicities.

122 s of HDP-P-GCV and hexadecyloxypropyl-cyclic cidofovir (HDP-cCDV).

123 Cidofovir (HPMPC) is a potent long-acting anticytomegalo

124 d into two topical treatment groups: I, 0.5% cidofovir; II, control vehicle.

125 with wild-type virus with the antiviral drug cidofovir, implicating virus replication and not an inde

126 e was no change in the kinetic parameters of cidofovir in Mrp4 knockout mice.

127 evaluate the safety and antiviral effects of cidofovir in patients with AIDS and asymptomatic sheddin

128 tion in immunosuppression and treatment with cidofovir in the majority.

129 ere resistant to topical treatment with 0.5% cidofovir in the rabbit ocular model.

130 efficacy of the drug 1-O-hexadecyloxypropyl-cidofovir in the RPV/rabbit model and found that an oral

131 with those showing reduced susceptibility to cidofovir in vitro.

132 These data indicate that cidofovir induces rapid cell death through apoptosis in

133 th normal saline were administered with each cidofovir infusion.

134 show that sT sensitizes MCPyV replication to cidofovir inhibition.

135 Cidofovir is a nucleotide analogue of cytosine that has

136 Cidofovir is preemptively used for controlling adenovire

137 Cidofovir is widely used to treat BKVAN, but the magnitu

138 CMX001, an orally active lipid conjugate of cidofovir, is 50 times more active in vitro against herp

139 ovir, intravenous foscarnet, and intravenous cidofovir, is effective.

140 8 tLM, V, a,, = 46.0 pmol/106 cells min) and cidofovir (K, = 58.0 /iM, Vt,ax = 103 pmol/106 cells * m

141 een explored including the adjunctive use of cidofovir, leflunomide, fluoroquinolones, and intravenou

142 egalovirus than HSV-1, liposome-encapsulated cidofovir may prove to be effective local therapy for AI

143 (e.g. Maraviroc, Abacavir, Telbivudine, and Cidofovir) may inhibit Ebola RNA-directed RNA polymerase

144 alone (n=17) or leflunomide plus a course of cidofovir (n=9) and followed them for six to forty month

145 Forty-one episodes (18 = brincidofovir; 23 = cidofovir) of antiviral therapy were observed in 27 pati

146 drugs (NSAIDs) on the antiviral activity of cidofovir on adenovirus replication and the formation of

147 One inoculation of 100 mg/kg cidofovir on day 0, 2, or 4, with respect to aerosol inf

148 hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir) on the EBV-associated tumor nasopharyngeal ca

149 CT/1.0% NH4Cl, 0.1% NCT/0.1% NH4Cl, and 0.5% cidofovir or saline.

150 =8 microM and <30 microM and sensitivity to cidofovir, or high-level ganciclovir-resistant, which ha

151 treated with 2.5%, 2.0%, and 1.0% NCT; 0.5% cidofovir; or saline.

152 developed agents valacyclovir, famciclovir, cidofovir, oral and intraocular ganciclovir, adefovir, r

153 only 2 (9%) major virological responses with cidofovir (P < .0001).

154 om 0.18 to 1.85 microg/mL, whereas those for cidofovir ranged from 0.018 to 5.47 microg/mL.

155 Compared to the control, treatment with 0.5% cidofovir reduced the following: mean Ad titer (days 1 t

156 reatment of the mice with the antiviral drug cidofovir reduced the numbers of effector and memory cel

157 Despite treatment with cidofovir, reduced immunosuppression and maintenance the

158 ation early in infection using the antiviral cidofovir rescued CD8(+) T cell cytokine production and

159 al specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when i

160 Mutations conferring ganciclovir and cidofovir resistance were detected in CMV from the aqueo

161 reference (IC50 = 6.2 micrograms/ml), stable cidofovir-resistant variants showed fivefold to eightfol

162 of pp71 or treatment with the antiviral drug cidofovir resulted in decreased expression and secretion

163 Cidofovir (S-HPMPC) is a potent broad-spectrum antiviral

164 ptide (12, 13) tyrosine P-O esters of cyclic cidofovir ((S)-cHPMPC, 4) and its cyclic adenine analogu

165 FST-100 and 0.5% cidofovir significantly (P<0.05) reduced viral titers co

166 In vivo, 3% ddC, 2% ddC, and 0.5% cidofovir significantly reduced the number of Ad5-positi

167 patients to topical treatment with either 1% cidofovir (supplied as a gel in a 10 g tube, to last 6 w

168 Thus, no significant changes in cidofovir susceptibilities have been noted for HCMV duri

169 red a borderline decrease in ganciclovir and cidofovir susceptibility, while Q578L and G841S conferre

170 When compared with the alkoxyalkyl esters of cidofovir, the corresponding alkoxyalkyl esters of (S)-H

171 Excluding patients with previous cidofovir therapy did not significantly alter the time c

172 In addition, cidofovir therapy may be useful in the treatment of some

173 Cidofovir therapy provided significant benefits in lesio

174 tained after 14.3 weeks (mean) of first-line cidofovir therapy showed complete susceptibility to cido

175 tinitis progression in patients that were on cidofovir therapy when sensitive isolates were compared

176 ithin 4 to 12 weeks (after 1-4 doses) of the cidofovir therapy, and all patients remain with stable r

177 h CMV retinitis and is unrelated to previous cidofovir therapy.

178 ained after 17.3 weeks (mean) of second-line cidofovir therapy.

179 For Cidofovir, these indices were, respectively, 63.9+/-17.2

180 :1 (five rabbits per group) to FST-100, 0.5% cidofovir, tobramycin/dexamethasone (Tobradex; Alcon Lab

181 he kinetics of para-aminohippurate (PAH) and cidofovir transport was examined along with its effect o

182 these residues on p-aminohippurate (PAH) and cidofovir transport were assessed by point mutations in

183 ular alphaKG competitively inhibited PAH and cidofovir transport with Ki values ( approximately 5 muM

184 Viral shedding ceased in 13 (87%) of 15 cidofovir-treated and 0 of 9 placebo-treated patients (P

185 pplication site reactions occurred in 25% of cidofovir-treated and 20% of placebo-treated patients; n

186 Ten of 20 cidofovir-treated and none of 10 placebo-treated patient

187 treated animals and were similar to those in cidofovir-treated animals.

188 Cidofovir-treated eyes received the authors' standard ci

189 ere treated four times daily for 7 days, and cidofovir-treated eyes were treated twice daily for 7 da

190 ferences in adenovirus replication among the cidofovir-treated groups (I, II, and III), nor were ther

191 Compared with the control group, all cidofovir-treated groups demonstrated significant antivi

192 ng or >50% decreased area (P = .008); 30% of cidofovir-treated patients versus 0 placebo recipients h

193 For cidofovir-treated patients, median time to complete or g

194 Cidofovir-treated recipients displayed a higher viral lo

195 Median lesion area decreases were 58% for cidofovir-treated versus 0 for placebo-treated patients

196 ber of satellite lesions than was parenteral cidofovir treatment (100 mg/kg/day, given every 3 days).

197 duction alone, based on best available data, cidofovir treatment and immunosuppression reduction for

198 d 45 years and above with BKVAN who received cidofovir treatment compared with those who received sta

199 included immunosuppression minimization plus cidofovir treatment for BK nephropathy.

200 significantly more efficacious than the 0.5% cidofovir treatment in the parameters listed above.

201 Cidofovir treatment was discontinued in 10 of 41 patient

202 Topical cidofovir treatment was superior to parenteral treatment

203 Combining topical and parenteral cidofovir treatments provided the greatest reduction in

204 Within the treatment groups, the 1% and 0.5% cidofovir treatments were significantly more effective t

205 Topical 0.5% cidofovir twice daily for 7 days demonstrated significan

206 as to determine the efficacy of topical 0.5% cidofovir twice daily for 7 days on the replication of m

207 ups (16 rabbits/group) were evaluated: I, 1% cidofovir, twice daily for 7 days; II, 0.5% cidofovir, t

208 cidofovir, twice daily for 7 days; II, 0.5% cidofovir, twice daily for 7 days; III, 3% acyclovir oin

209 ginally identified as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested significantly h

210 idofovir mediated major responses in 9 of 11 cidofovir-unresponsive patients and resulted in complete

211 ly (adefovir, used to treat hepatitis B, and cidofovir, used to treat cytomegalovirus infections) wer

212 of ocular toxicity associated with systemic cidofovir (Vistide), sildenafil (Viagra), vigabatrin (Sa

213 he virus until these levels were attained or cidofovir was added.

214 rence to monitoring of renal function before cidofovir was administered and concomitant administratio

215 In 15 of 32 affected eyes, intravitreous cidofovir was administered as the initial treatment for

216 In mice, cidofovir was also eliminated via the urine by tubular s

217 Cidofovir was efficacious in delaying progression of pre

218 ent uptake of adefovir and tenofovir but not cidofovir was observed only in the membrane vesicles exp

219 passages (1 to 13) at each concentration of cidofovir was performed to obtain robust infectious viru

220 Cidofovir was significantly more effective than NCT in s

221 ant increase in IC50 value was observed when cidofovir was the substrate, but not PAH (a substrate-de

222 y-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit mode

223 ase-case, the incremental health benefits of cidofovir were 0.0061 life-years saved (2.2 days), with

224 Differences in handling of PAH and cidofovir were also observed for the Y230F mutant.

225 Consequently, adefovir and cidofovir were approximately 500-fold and 400-fold more

226 FST-100 and 0.5% cidofovir were both equally effective in reducing viral

227 ous degrees of resistance to ganciclovir and cidofovir were conferred by mutations D301N, N410K, D413

228 nhibitory concentrations (IC(50)) of ddC and cidofovir were determined using standard plaque-reductio

229 Intravitreal levels of cidofovir were low (0.7 microgram/mL) but detectable 120

230 elapsing retinitis) therapy with intravenous cidofovir were obtained from three clinical trials for i

231 Little uptake was determined for cidofovir, whereas PAH uptake was similar to wild-type h

232 The cyclic prodrug of cidofovir, which exhibits reduced in vivo nephrotoxicity